Fate Therapeutics IncNASDAQ:FATE
- LAST PRICE4.2550
- TODAY'S CHANGE (%)0.0150 (0.3538%)
- Bid / Lots4.2500/ 16
- Ask / Lots4.2600/ 17
- Open / Previous Close4.2600 / 4.2400
- Day Range
- 52 Week Range
- Volume666,216
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FATE |
|---|---|---|
| 09:32 ET | 31268 | 4.3 |
| 09:34 ET | 8890 | 4.2358 |
| 09:36 ET | 5661 | 4.18 |
| 09:38 ET | 23927 | 4.185 |
| 09:39 ET | 11788 | 4.16 |
| 09:41 ET | 7730 | 4.155 |
| 09:43 ET | 1289 | 4.16 |
| 09:45 ET | 4952 | 4.16 |
| 09:48 ET | 5685 | 4.17 |
| 09:50 ET | 8470 | 4.155 |
| 09:52 ET | 23696 | 4.14 |
| 09:54 ET | 8960 | 4.1493 |
| 09:56 ET | 9076 | 4.12 |
| 09:57 ET | 1123 | 4.125 |
| 09:59 ET | 1100 | 4.125 |
| 10:01 ET | 7760 | 4.125 |
| 10:03 ET | 4334 | 4.125 |
| 10:06 ET | 1482 | 4.1088 |
| 10:08 ET | 1877 | 4.08 |
| 10:10 ET | 7142 | 4.075 |
| 10:12 ET | 16214 | 4.04 |
| 10:14 ET | 6855 | 4.08 |
| 10:15 ET | 5934 | 4.09 |
| 10:17 ET | 35124 | 4.17 |
| 10:19 ET | 1271 | 4.17 |
| 10:21 ET | 25956 | 4.2 |
| 10:24 ET | 4273 | 4.205 |
| 10:26 ET | 5889 | 4.2 |
| 10:28 ET | 15890 | 4.24 |
| 10:30 ET | 2245 | 4.225 |
| 10:32 ET | 12161 | 4.21 |
| 10:33 ET | 1013 | 4.21 |
| 10:35 ET | 10605 | 4.21 |
| 10:37 ET | 23936 | 4.22 |
| 10:39 ET | 1894 | 4.21 |
| 10:42 ET | 700 | 4.21 |
| 10:44 ET | 18490 | 4.24 |
| 10:46 ET | 1576 | 4.24 |
| 10:48 ET | 6859 | 4.225 |
| 10:50 ET | 5284 | 4.23 |
| 10:51 ET | 4385 | 4.23 |
| 10:53 ET | 6215 | 4.2205 |
| 10:55 ET | 2727 | 4.225 |
| 10:57 ET | 4999 | 4.25 |
| 11:00 ET | 3550 | 4.2503 |
| 11:02 ET | 4182 | 4.24 |
| 11:04 ET | 6091 | 4.24 |
| 11:06 ET | 2300 | 4.25 |
| 11:08 ET | 623 | 4.245 |
| 11:09 ET | 3100 | 4.255 |
| 11:11 ET | 11237 | 4.24 |
| 11:13 ET | 4122 | 4.24 |
| 11:15 ET | 27518 | 4.26 |
| 11:18 ET | 7949 | 4.27 |
| 11:20 ET | 1971 | 4.27 |
| 11:22 ET | 6305 | 4.26 |
| 11:24 ET | 5107 | 4.265 |
| 11:26 ET | 9837 | 4.2798 |
| 11:27 ET | 9990 | 4.27 |
| 11:29 ET | 4250 | 4.28 |
| 11:31 ET | 700 | 4.2798 |
| 11:33 ET | 4744 | 4.285 |
| 11:36 ET | 12933 | 4.27 |
| 11:38 ET | 2400 | 4.265 |
| 11:40 ET | 4898 | 4.24 |
| 11:42 ET | 9439 | 4.24 |
| 11:44 ET | 5852 | 4.235 |
| 11:45 ET | 3026 | 4.24 |
| 11:47 ET | 1812 | 4.235 |
| 11:49 ET | 792 | 4.235 |
| 11:51 ET | 4200 | 4.25 |
| 11:54 ET | 2271 | 4.245 |
| 11:56 ET | 600 | 4.245 |
| 11:58 ET | 1704 | 4.2498 |
| 12:00 ET | 6025 | 4.2598 |
| 12:02 ET | 2659 | 4.26 |
| 12:03 ET | 2504 | 4.26 |
| 12:05 ET | 2373 | 4.25 |
| 12:07 ET | 9025 | 4.245 |
| 12:09 ET | 3405 | 4.255 |
| 12:12 ET | 837 | 4.255 |
| 12:14 ET | 1608 | 4.255 |
| 12:16 ET | 800 | 4.26 |
| 12:18 ET | 2613 | 4.25 |
| 12:20 ET | 1675 | 4.255 |
Today
May 10, 2024
DJ Fate Therapeutics Is Maintained at Buy by Canaccord Genuity, from 2:48PM ET on Friday May 10, 2024 by Dow Jones
2:48PM ET on Friday May 10, 2024 by Dow JonesDJ Fate Therapeutics Is Maintained at Market Perform by BMO Capital, from 11:27AM ET on Friday May 10, 2024 by Dow Jones
11:27AM ET on Friday May 10, 2024 by Dow JonesDJ Fate Therapeutics Is Maintained at Neutral by Piper Sandler, from 9:28AM ET on Friday May 10, 2024 by Dow Jones
9:28AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Fate Therapeutics Inc | 482.6M | -2.2x | --- |
Editas Medicine Inc | 493.4M | -2.8x | --- |
ADC Therapeutics SA | 397.3M | -1.5x | --- |
Urogen Pharma Ltd | 497.9M | -4.0x | --- |
Poseida Therapeutics Inc | 335.4M | -2.4x | --- |
Contineum Therapeutics Inc | 400.5M | 17.1x | --- |
Company Information
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Contact Information
- Headquarters
- 12278 Scripps Summit DriveSAN DIEGO, CA, United States 92131
- Phone
- 858-875-1803
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- William Rastetter
- President, Chief Executive Officer, Director
- John Wolchko
- Independent Vice Chairman of the Board
- John Mendlein
- Chief Financial Officer
- Edward Dulac
- General Counsel and Corporate Secretary
- Cindy Tahl
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $482.6M |
|---|---|
Revenue (TTM) | $6.5M |
Shares Outstanding | 113.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.93 |
EPS | $-1.92 |
Book Value | $3.74 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 74.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,287.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
